As you know, there are two new San Diego "inbreeding" connections for Axiom. To my knowledge, the Arena deal was never finalized. But, I've read SEC documents that clearly indicate that Axiom got the cash. I guess that the simple explanation would be that DD is ongoing??? The attorneys here may be able to pick up the trail better than I can, or decipher signals on the trail.
I believe that OSIP felt that a license from Cyanamid was necessary to complement the Cadus yeast screen. I am not clear if that relates only to GPCRs.
That is *all* I know. An analysis of Arena is on my "to do" list, sorry.
The other new connection is Syrrx, with David Webb moving there to assume the head honcho slot in Drug Discovery. Tomato mentioned a public company, TELK. A reverse merge with a private company, accompanied by an IPO, also makes sense to me.
>> Could you be describing Arena as well? <<
Do you mean as an analogy to KDUS? Cash rich, under-valued? Sure. Otherwise, no. As a substitute for TELK? Arena is anything other than in need of cash, so...... no. But, that doesn't mean that it wouldn't make sense for them to do a 3X for KDUS. It just wouldn't seem to be as compelling, IMO. |
